ARHGAP4 Antibody

What is ARHGAP4 and what are its key functional domains?

ARHGAP4 (Rho GTPase-activating protein 4) belongs to the Rho-GAP family and contains three primary structural domains: the F-BAR domain, the Rho-GAP domain, and the SH3 domain. Each domain serves distinct functions in protein-protein interactions and cellular signaling. The Rho-GAP domain is primarily responsible for inactivating Rho family GTPases, while the SH3 domain mediates protein interactions. Recent research has demonstrated that both the Rho-GAP and SH3 domains are essential for ARHGAP4's ability to down-regulate focal adhesions through modulation of paxillin expression .

What protein interactions has ARHGAP4 been shown to participate in?

ARHGAP4 forms a complex with septins SEPT2 and SEPT9 through specific domain interactions. Research using coimmunoprecipitation and mass spectrometry has confirmed that:

• ARHGAP4 binds to both SEPT2 and SEPT9 through its Rho-GAP and SH3 domains

• SEPT2 and SEPT9 also interact with each other independent of ARHGAP4

• This tripartite complex plays a crucial role in regulating integrin-mediated focal adhesions

The following table summarizes the key protein interactions:

How should ARHGAP4 antibodies be stored and handled for optimal results?

For optimal performance and longevity of ARHGAP4 antibodies, researchers should adhere to the following storage and handling recommendations:

• Long-term storage: Maintain at -20°C for up to one year

• Short-term storage: Store at 4°C for up to one month when in frequent use

• Avoid repeated freeze-thaw cycles as they significantly reduce antibody effectiveness

• Most commercial formulations are available in PBS containing 50% glycerol and 0.02% sodium azide for stability

What are the validated applications for ARHGAP4 antibodies?

Based on current research and commercial availability, ARHGAP4 antibodies have been validated for several experimental applications:

• Western Blotting (WB): Typically used at dilutions of 1:500-2000

• Enzyme-Linked Immunosorbent Assay (ELISA): Optimal at dilutions of 1:5000-20000

• Immunocytochemistry (ICC): For visualization of ARHGAP4 localization

• Immunoprecipitation (IP): Critical for studying protein-protein interactions as demonstrated in ARHGAP4-SEPT2-SEPT9 complex studies

Researchers should note that each specific antibody may have different optimal conditions, and validation for each application in your specific cell type is recommended.

What are the best protocols for visualizing ARHGAP4 in relation to focal adhesions?

For effective visualization of ARHGAP4 in relation to focal adhesions, consider the following methodological approach:

• Sample Preparation: Fix cells with 4% paraformaldehyde and permeabilize with 0.1% Triton X-100

• Co-staining Strategy: Use ARHGAP4 antibody alongside focal adhesion markers such as paxillin, FAK, or phosphorylated versions (pY397-FAK, pY118-paxillin)

• Imaging Considerations: Employ high-resolution confocal microscopy, as ARHGAP4 does not strongly colocalize with paxillin at focal adhesions (Pearson correlation coefficient ~0.1)

Note that research indicates ARHGAP4 may not be directly localized to focal adhesions but instead regulates their formation through interactions with other proteins. This explains why colocalization studies may not show strong overlap between ARHGAP4 and focal adhesion markers .

How can researchers study the role of ARHGAP4 in focal adhesion dynamics?

To effectively investigate ARHGAP4's role in focal adhesion dynamics, consider implementing the following experimental approaches:

• Domain-specific functional analysis: Create and express domain deletion mutants (ΔF-BAR, ΔRho-GAP, ΔSH3) to identify which domains are critical for specific functions

• Quantitative focal adhesion analysis: Measure the number, size, and distribution of focal adhesions using immunofluorescence for paxillin or other FA markers

• Phosphorylation status assessment: Monitor phosphorylation of FAK at Y397 and paxillin at Y118 via Western blotting to assess focal adhesion activation

Research has shown that ARHGAP4 knockdown leads to:

• Increased expression of paxillin and FAK

• Enhanced phosphorylation of FAK at Y397 and paxillin at Y118

• Increased total number but decreased size of individual focal adhesions

• Redistribution of focal adhesions toward cell periphery

What is the significance of ARHGAP4 as a prognostic biomarker, and how can antibodies be used in this context?

ARHGAP4 has demonstrated potential as a prognostic biomarker, particularly in colorectal cancer with liver metastases. Recent research involving 251 patients undergoing resection of colon liver metastases revealed:

For research applications in this context, immunohistochemistry (IHC) using validated ARHGAP4 antibodies is the recommended approach. Researchers should establish clear scoring criteria for defining "high" versus "low" expression levels to maintain consistency across studies.

How do experimental conditions affect ARHGAP4 antibody specificity and sensitivity?

Several experimental factors can influence the specificity and sensitivity of ARHGAP4 antibody detection:

• Epitope accessibility: The ARHGAP4 antibody's target epitope (for example, amino acids 180-260 in some commercial antibodies) may be masked by protein-protein interactions or conformational changes

• Fixation method: Different fixation protocols can affect epitope preservation and accessibility

• Cell type considerations: Expression levels and post-translational modifications of ARHGAP4 vary across cell types, potentially affecting antibody binding

• Blocking conditions: Optimization of blocking buffers is essential to reduce background while maintaining specific signal

When troubleshooting, researchers should consider validating antibody specificity through knockout or knockdown controls and testing multiple antibodies targeting different epitopes of ARHGAP4.

What methodological approaches are most effective for studying ARHGAP4's role in cell migration and invasion?

Research has demonstrated that ARHGAP4 plays a significant role in regulating cell migration and invasion. To effectively study these processes, consider the following experimental approaches:

• Gene silencing experiments: Use siRNA or shRNA targeting ARHGAP4 to assess phenotypic changes in migration and invasion capabilities

• Domain-specific mutant expression: Express domain deletion mutants to identify which domains are essential for migration/invasion regulation

• Integrin expression analysis: Monitor changes in Integrin Beta 1 expression, as ARHGAP4 has been shown to regulate this critical adhesion molecule

• Microenvironment-dependent assays: Test migration and invasion in different extracellular matrix compositions, as ARHGAP4's effects depend on the availability of suitable ligands for Integrin Beta 1

Research findings indicate that silencing ARHGAP4 or overexpressing its regulators SEPT2 and SEPT9 enhances both cell migration and invasion, potentially through reorganization of focal adhesions and upregulation of Integrin Beta 1 .

How can researchers reconcile contradictory findings regarding ARHGAP4's role in different cell types?

The literature contains seemingly contradictory findings regarding ARHGAP4's role in different cellular contexts. To address these discrepancies, researchers should consider:

• Cell-type specific expression levels: Examine baseline ARHGAP4 expression across different cell types using Western blotting

• Interaction partner analysis: Identify cell-type specific binding partners that might modify ARHGAP4 function

• Signaling pathway context: Determine which signaling pathways are active in each cell type that might influence ARHGAP4 function

• Experimental design considerations: Account for differences in methodology, including:

  • 2D versus 3D culture systems

  • Substrate stiffness and composition

  • Temporal dynamics of measurements

Research has shown that ARHGAP4 can both promote epithelial characteristics and inhibit migration in some contexts, while its silencing can induce mesenchymal features reminiscent of epithelial-mesenchymal transition (EMT) in others . This versatility highlights the context-dependent nature of ARHGAP4 function.

What criteria should be used when selecting an ARHGAP4 antibody for specific applications?

When selecting an ARHGAP4 antibody for research, consider these critical factors:

• Target epitope location: Antibodies targeting different regions of ARHGAP4 may have varying effectiveness depending on your experimental question

• Validation evidence: Review published literature demonstrating use of the antibody in applications similar to yours

• Species reactivity: Ensure compatibility with your experimental model system

• Clone type: Consider whether a monoclonal or polyclonal antibody is more suitable for your application

• Application-specific validation: Confirm the antibody has been validated for your specific application (WB, IHC, IF, etc.)

For example, some commercial antibodies target the amino acid range 180-260 of human ARHGAP4, which may have specific advantages for certain applications .

What are effective strategies for troubleshooting inconsistent results with ARHGAP4 antibodies?

When encountering inconsistent results with ARHGAP4 antibodies, implement these troubleshooting approaches:

• Antibody validation: Confirm antibody specificity using positive and negative controls

• Protocol optimization:

  • Adjust antibody concentration (typical working dilutions range from 1:500-2000 for WB and 1:5000-20000 for ELISA)

  • Modify incubation times and temperatures

  • Test different blocking reagents to reduce background

• Sample preparation: Ensure consistent protein extraction and handling procedures

• Domain-specific considerations: If studying specific domains, consider whether your antibody's epitope is in a region affected by your experimental manipulation

Remember that ARHGAP4 interacts with multiple proteins, including SEPT2 and SEPT9, which may affect epitope accessibility depending on experimental conditions .